Clear Street on BioNTech (BNTX): 'BNT323 Clears Low Bar in Breast Cancer, But Incremental Validation Welcome'
Tweet Send to a Friend
Clear Street analyst Bill Maughan reiterated a Buy rating and $185.00 price target on BioNTech (NASDAQ: BNTX).The analyst comments "Shares ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
